×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BMY – bristol-myers squibb company (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BMY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/19
09:27 am
bmy
These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity [Yahoo! Finance]
Low
Report
These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity [Yahoo! Finance]
3/19
08:30 am
bmy
Bristol Myers Squibb Tests New Protein Degradation Cancer Drug In Humans [Yahoo! Finance]
Low
Report
Bristol Myers Squibb Tests New Protein Degradation Cancer Drug In Humans [Yahoo! Finance]
3/19
08:19 am
bmy
BioIVT to Showcase ADME-Tox and NAMs Expertise at Spring 2026 Industry Events [Yahoo! Finance]
Low
Report
BioIVT to Showcase ADME-Tox and NAMs Expertise at Spring 2026 Industry Events [Yahoo! Finance]
3/19
06:59 am
bmy
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
Low
Report
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
3/18
10:36 am
bmy
Don't Miss This 14% Yield And This Pharma Value Stock [Seeking Alpha]
Low
Report
Don't Miss This 14% Yield And This Pharma Value Stock [Seeking Alpha]
3/18
05:09 am
bmy
Bristol-Myers Squibb: The Boring Dividend Stock I'd Happily Hold Through Any Crash [Yahoo! Finance]
Low
Report
Bristol-Myers Squibb: The Boring Dividend Stock I'd Happily Hold Through Any Crash [Yahoo! Finance]
3/17
12:30 pm
bmy
Bristol Myers Squibb (BMY) had its price target raised by HSBC Holdings plc from $53.00 to $60.00. They now have a "hold" rating on the stock.
Low
Report
Bristol Myers Squibb (BMY) had its price target raised by HSBC Holdings plc from $53.00 to $60.00. They now have a "hold" rating on the stock.
3/14
09:20 pm
bmy
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference [Yahoo! Finance]
Low
Report
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/6/2026
04:05 pm
bmy
bristol-myers squibb company
BEAT
Report
-1.9%
bristol-myers squibb company
2/5/2026
04:03 pm
bmy
bristol-myers squibb company
BEAT
Report
4.9%
bristol-myers squibb company
2/5/2026
07:33 am
bmy
bristol-myers squibb company
BEAT
Report
1.7%
bristol-myers squibb company
10/31/2025
04:03 pm
bmy
bristol-myers squibb company
BEAT
Report
-0.1%
bristol-myers squibb company
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/12
04:25 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Hickey Benjamin
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Hickey Benjamin
3/12
04:24 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Shibutani Hiroshi Chris
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Shibutani Hiroshi Chris
3/12
04:24 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Massacesi Cristian
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Massacesi Cristian
3/12
04:23 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Short Bartie Wendy
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Short Bartie Wendy
3/12
04:23 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Shanahan Karin
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Shanahan Karin
3/12
04:22 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Plenge Robert M
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Plenge Robert M
3/12
04:19 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Lenkowsky Adam
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Lenkowsky Adam
3/12
04:19 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Meyers Gregory Scott
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Meyers Gregory Scott
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/24
Bristol-Myers releases mixed Opdivo lung cancer results [Reuters]
10.2%
3/12 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA 7.9%
3/25 Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05 5.9%
4/8 Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer 4.3%
3/3 Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology 3.9%
4/3 Form 3 BRISTOL MYERS SQUIBB CO For: Mar 30 Filed by: Mily Elizabeth 3.4%
8/25 Better Buy: Biogen vs. Celgene [The Motley Fool] 3.1%
3/31 Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA 2.8%
4/20 Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma 2.8%
8/15 What Has Led Bristol-Myers Squibb's Stock To Fall More Than 35% Over The Last 3 Years? [Forbes] 2.7%
3/12 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA 7.9%
3/25 Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05 5.9%
4/8 Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer 4.3%
3/3 Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology 3.9%
4/3 Form 3 BRISTOL MYERS SQUIBB CO For: Mar 30 Filed by: Mily Elizabeth 3.4%
8/25 Better Buy: Biogen vs. Celgene [The Motley Fool] 3.1%
3/31 Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA 2.8%
4/20 Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma 2.8%
8/15 What Has Led Bristol-Myers Squibb's Stock To Fall More Than 35% Over The Last 3 Years? [Forbes] 2.7%
TOP News Decliners
6/24
Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
-7.8%
3/11 Nationwide class actions are safe, thanks to the D.C. and 7th Circuits [Reuters] -7.1%
10/22 Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Yahoo! Finance News] -4.9%
3/6 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 04 Filed by: Elicker John E -4.4%
3/20 Bristol-Myers Squibb, Sanofi strike out in bid to stop Plavix litigation [Seeking Alpha] -4.3%
3/18 Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development -4.3%
2/26 Form 4 BRISTOL MYERS SQUIBB CO For: Feb 03 Filed by: Metcalfe Kathryn -4.0%
3/16 BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug [Investor's Business Daily] -3.6%
4/7 Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. -3.6%
4/20 Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials [The Motley Fool] -3.5%
3/11 Nationwide class actions are safe, thanks to the D.C. and 7th Circuits [Reuters] -7.1%
10/22 Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Yahoo! Finance News] -4.9%
3/6 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 04 Filed by: Elicker John E -4.4%
3/20 Bristol-Myers Squibb, Sanofi strike out in bid to stop Plavix litigation [Seeking Alpha] -4.3%
3/18 Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development -4.3%
2/26 Form 4 BRISTOL MYERS SQUIBB CO For: Feb 03 Filed by: Metcalfe Kathryn -4.0%
3/16 BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug [Investor's Business Daily] -3.6%
4/7 Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. -3.6%
4/20 Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials [The Motley Fool] -3.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: